Evidence map›Paper›PMID 40787264›Full record

ArticleF1000Research2021

Bich Vu Thi Ngoc, Sylvain Brisse, Trinh Dao Tuyet, Dung Vu Tien Viet, Kathryn E Holt, Trung Nguyen Vu, Huong Tran Thi Kieu, Diep Nguyen Thi Ngoc, H Rogier van Doorn, Heiman F L Wertheim

Abstract read
In one paragraph

Article in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. F1000Research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bich Vu Thi NgocOxford University Clinical Research Unit - Hanoi, Hanoi, Vietnam.ORCID 0000-0001-6870-4096
Sylvain BrisseFrench National Centre for Scientific Research, Paris, France.
Trinh Dao TuyetNational Hospital of Tropical Diseases, Hanoi, Vietnam.
Dung Vu Tien VietOxford University Clinical Research Unit - Hanoi, Hanoi, Vietnam.
Kathryn E HoltDepartment of Biochemistry & Molecular Biology, Centre for Systems Genomics, University of Melbourne, Melbourne, Australia.
Trung Nguyen VuNational Hospital of Tropical Diseases, Hanoi, Vietnam.
Huong Tran Thi KieuOxford University Clinical Research Unit - Hanoi, Hanoi, Vietnam.
Diep Nguyen Thi NgocOxford University Clinical Research Unit - Hanoi, Hanoi, Vietnam.
H Rogier van DoornOxford University Clinical Research Unit - Hanoi, Hanoi, Vietnam.ORCID 0000-0002-9807-1821
Heiman F L WertheimOxford University Clinical Research Unit - Hanoi, Hanoi, Vietnam.

Funding

Wellcome TrustWellcome Trust 49-12
6 · The paper itself

Abstract

Introduction: Recent reports indicate the emergence of community-acquired pneumonia associated with K64- Methods: We included 93 Results: The most common detected capsule types were K1 (39/203, 19.2%, mainly ST23) and K2 (31/203, 15.3%, multiple STs: ST65, ST86, ST380). We found significantly more K2 isolates among invasive in comparison to commensal isolates (22.6% vs 9%, p = 0.01) but no significant difference was observed between invasive and commensal K1 isolates (14.5% vs 24.7%, p = 0.075). K64 with varying sequence types were predominantly seen among invasive Conclusion: Our study confirms that capsule type K64

Indexed as

Bacterial CapsulesKlebsiella InfectionsKlebsiella pneumoniaeAdultAnti-Bacterial AgentsFemaleHumansMaleMicrobial Sensitivity TestsMultilocus Sequence TypingVietnamAnti-Bacterial Agentscapsule typecarbapenem-resistantcommunity-acquired infectionsK64Klebsiella pneumoniae

Identifiers

PMID40787264
PMCPMC12335726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.